New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
06:04 EDTMYGN, SFESafeguard Scientifics expects $40M from Crescendo sale to Myriad
Safeguard Scientifics (SFE) announced that its partner company, Crescendo Bioscience, signed an amended agreement to be acquired by Myriad Genetics (MYGN) for $270M, in cash, minus $25M for the repayment of a loan made to Crescendo by Myriad in 2011. The transaction is expected to close in the fiscal quarter ending March 31, 2014. Safeguard expects to receive approximately $40M in aggregate cash proceeds pending final closing calculations. Safeguard has deployed $11M in Crescendo since December 2012 and has a 13% primary ownership position. Stephen Zarrilli, CEO at Safeguard, said, "Safeguard begins 2014 with tremendous momentum, having recently announced exits transactions for Safeguard’s partner companies Alverix, Inc., NuPathe Inc., ThingWorx, Inc., and now Crescendo Bioscience. We continue to build a robust pipeline of new and exciting opportunities while we are equally focused on identifying well-timed exits to maximize value for our shareholders."
News For SFE;MYGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 14, 2015
12:05 EDTSFESafeguard Scientifics management to meet with Barrington
Subscribe for More Information
April 11, 2015
14:20 EDTMYGNWilliam Blair diagnostic services analyst holds analyst/industry conference call
Analysts, along with Dr. Todd Cohen, provide an industry update on an Analyst/Industry conference call to be held on April 16 at 3 pm.
April 8, 2015
08:45 EDTMYGNLife Sciences group well positioned heading into Q1 earnings, says Cowen
Cowen said the Life Sciences sector looks well positioned heading into Q1 earnings despite the group outperforming the broader market recently. The firm believes headwinds have intensified and multiples have stretched, but they see the downside risk as limited with upside risk dependent on improving end-market commentary, new products and milestones, and new details on capital deployment. Stocks in the space include Affymetrix (AFFX), Fluidigm (FLDM), GenMark (GNMK), Myriad Genetics (MYGN) and Quidel (QDEL).

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use